In our study, we detect a high level of serum IL-6 concentration in diabetic PAD patients, but after cell treatment, IL-6 concentration in CD133+ group remained at lower level than in control group within four weeks (P = 0.026, 0.000, and 0.001 at 1, 2, and 4 weeks), indicating a profounder anti-inflammatory regulation effect with the infusion of CD133+ cells. The gene discussed is IL6; the disease is peripheral arterial disease.